Physician profile

Edwin Korouri

Brooklyn, NY

NPI 1255190393

$452.04

in general payments reported to CMS, 2019-2025

8 companies · $452 in 2025

The $452 reported for 2025 was more than what 77% of providers received nationally.

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$452.04

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Ucb, INC. $149.10 2025 Bimzelx
Polynovo North America LLC $115.41 2025 Novosorb Btm
Arcutis Biotherapeutics, INC. $49.96 2025 Zoryve
Botanix Sb INC $37.28 2025 Sofdra
Takeda Pharmaceuticals U.S.A., INC. $29.70 2025
Pfizer INC. $28.00 2025
Amgen INC. $24.04 2025 Otezla
Chiesi USA, INC. $18.55 2025 Filsuvez

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Edwin Korouri

$452.04

in general payments reported 2019-2025

Years
2025
Top company
Ucb, INC.
Context
The $452 reported for 2025 was more than what 77% of providers received nationally.

https://glasscript.com/doctor/11963472/edwin-korouri

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.